Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Harmony Biosciences (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

Rhea-AI Summary

Harmony Biosciences (Nasdaq: HRMY) announced that its management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. A live webcast will be accessible via the investor page of the Harmony Biosciences website.

Harmony Biosciences is a pharmaceutical company focused on developing and commercializing therapies for patients with rare neurological diseases with unmet medical needs, headquartered in Plymouth Meeting, Pennsylvania.

Argus Aug 6 session 1 alert

+1.33% close to close 0.0x rel. volume Open Argus

Details

News Market Reaction – HRMY

$2.33B Market Cap

In the Aug 6 session, HRMY gained 1.33%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

HRMY's historical event 1084430 was followed by a 9.97% 24-hour move, giving this scheduling notice ...

Analysis

HRMY's historical event 1084430 was followed by a 9.97% 24-hour move, giving this scheduling notice a platform precedent. Key watchpoints were forthcoming disclosure and moderate short positioning as a volatility risk.

Key Figures

Announcement Date: August 6, 2026 Symposium Date: August 13, 2026 Fireside Chat Time: 1:30 p.m. ET

Announcement Date

August 6, 2026

Article publication

Symposium Date

August 13, 2026

Piper Sandler Virtual CNS Symposium

Fireside Chat Time

1:30 p.m. ET

August 13, 2026

Historical Context

5 past events · Latest: Jul 21

5 events

1. Jul 21

   Earnings date notice

   24h Move

   +10.0%

   Announced the date for second-quarter 2026 financial results and investor conference call.

2. Jul 16

   Revenue preannouncement

   24h Move

   -3.9%

   Preannounced record WAKIX revenue, reaffirmed guidance, and announced a CFO transition.

3. Jun 11

   Portfolio company sale

   24h Move

   -0.8%

   Paragon closed the Emalex sale to Teva with cash and milestone consideration.

4. Jun 11

   Poster presentations

   24h Move

   -0.8%

   Announced six posters covering narcolepsy, idiopathic hypersomnia, formulations, and safety outcomes.

5. May 27

   Investor conferences

   24h Move

   +2.2%

   Announced management fireside chats at two upcoming healthcare investor conferences.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.

A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com

Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Harmony Biosciences (HRMY) present at the Piper Sandler Virtual CNS Symposium in 2026?

Harmony Biosciences will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET. According to Harmony Biosciences, the event will feature its management team discussing the company and its activities.

How can investors access the Harmony Biosciences (HRMY) webcast for the August 13, 2026 Piper Sandler CNS event?

Investors can access the Harmony Biosciences webcast on the investor page of the company’s website. According to Harmony Biosciences, the fireside chat from the Piper Sandler Virtual CNS Symposium will be streamed online for remote viewing through its investor relations portal.

What type of company is Harmony Biosciences (HRMY) and what diseases does it focus on?

Harmony Biosciences is a pharmaceutical company focused on rare neurological diseases with unmet medical needs. According to Harmony Biosciences, it develops and commercializes innovative therapies aimed at helping patients with rare neurological conditions improve their quality of life.

Where is Harmony Biosciences (HRMY) headquartered and when was it established?

Harmony Biosciences is headquartered in Plymouth Meeting, Pennsylvania, and was established in 2017 by Paragon Biosciences. According to Harmony Biosciences, the company combines innovation and empathy to advance therapies for patients with rare neurological diseases.

Who are the investor and media contacts for Harmony Biosciences (HRMY) around the August 2026 Piper Sandler CNS Symposium?

Harmony Biosciences lists Brennan Doyle as Investor Contact and Cate McCanless as Media Contact. According to Harmony Biosciences, Doyle can be reached at 484-566-3685 and McCanless at 202-641-6086, with email addresses provided on the company’s announcement.